These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 17517050

  • 1. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
    Solas C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, Brunet C, Gastaut JA, Durand A, Lacarelle B, Poizot-Martin I.
    Br J Clin Pharmacol; 2007 Sep; 64(3):353-62. PubMed ID: 17517050
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.
    Curras V, Hocht C, Mangano A, Niselman V, Mariño Hernández E, Cáceres Guido P, Mecikovsky D, Bellusci C, Bologna R, Sen L, Rubio MC, Bramuglia GF.
    Pharmacology; 2009 Sep; 83(1):59-66. PubMed ID: 19052483
    [Abstract] [Full Text] [Related]

  • 3. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P.
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K, Legrand M, Taburet AM, Baron G, Goujard C, Mentré F, Cophar 1-ANRS 102 Trial Group.
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [Abstract] [Full Text] [Related]

  • 6. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS.
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
    Kappelhoff BS, Huitema AD, Sankatsing SU, Meenhorst PL, Van Gorp EC, Mulder JW, Prins JM, Beijnen JH.
    Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
    [Abstract] [Full Text] [Related]

  • 8. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K.
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [Abstract] [Full Text] [Related]

  • 9. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
    Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, McDade K, Zhang J, Burckart GJ.
    J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T.
    Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
    [Abstract] [Full Text] [Related]

  • 12. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.
    Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Céron D, Duval X, Mentré F, COPHAR2-ANRS 111 Study Group.
    Eur J Clin Pharmacol; 2009 Jul; 65(7):667-78. PubMed ID: 19440701
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
    Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ, van den Anker JN.
    Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
    Kappelhoff BS, Huitema AD, Crommentuyn KM, Mulder JW, Meenhorst PL, van Gorp EC, Mairuhu AT, Beijnen JH.
    Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
    [Abstract] [Full Text] [Related]

  • 17. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [Abstract] [Full Text] [Related]

  • 18. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM, COPHAR1-ANRS 102 Study Group.
    Clin Pharmacokinet; 2005 Dec; 44(12):1267-78. PubMed ID: 16372824
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.
    Lemaitre F, Bezian E, Goldwirt L, Fernandez C, Farinotti R, Varnous S, Urien S, Antignac M.
    Ther Drug Monit; 2012 Dec; 34(6):686-94. PubMed ID: 23131698
    [Abstract] [Full Text] [Related]

  • 20. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
    Song J, Kim MG, Choi B, Han NY, Yun HY, Yoon JH, Oh JM.
    Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.